Cargando…

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

SIMPLE SUMMARY: Treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs)—cetuximab and panitumumab—produced clinical benefits in a subset of patients with metastatic colorectal cancer (mCRC). Here, the authors investigated the relative expression and predictive value...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M., Modjtahedi, Helmout
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914886/ https://www.ncbi.nlm.nih.gov/pubmed/33562755 http://dx.doi.org/10.3390/cancers13040638

Ejemplares similares

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
por: Khelwatty, Said, et al.
Publicado: (2016)

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
por: Puvanenthiran, Soozana, et al.
Publicado: (2018)

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
por: Khelwatty, Said Abdullah, et al.
Publicado: (2019)

Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
por: Khelwatty, Said Abdullah, et al.
Publicado: (2014)

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
por: Puvanenthiran, Soozana, et al.
Publicado: (2016)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
por: Khan, Tanzeel, et al.
Publicado: (2020)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
por: Stanley, Aryan, et al.
Publicado: (2017)

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
por: Ioannou, Nikolaos, et al.
Publicado: (2013)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
por: Tong, Daniel, et al.
Publicado: (2021)

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
por: IOANNOU, NIKOLAOS, et al.
Publicado: (2016)

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer
por: Arias-Pinilla, Gustavo A., et al.
Publicado: (2018)

Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
por: Arias-Pinilla, Gustavo A., et al.
Publicado: (2020)

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS
por: Yang, Jing, et al.
Publicado: (2017)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
por: Tao, Huimin, et al.
Publicado: (2022)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations
por: Gollins, Simon, et al.
Publicado: (2017)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
por: Toledo, Rodrigo A., et al.
Publicado: (2016)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Zheng, Bobo, et al.
Publicado: (2019)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
por: Chan, Wing-Lok, et al.
Publicado: (2014)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
por: Liu, Shousheng, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
por: Han, Jiaqi, et al.
Publicado: (2020)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
por: Wang, Lu, et al.
Publicado: (2020)

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Han, Yu Na, et al.
Publicado: (2022)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
por: Wang, Huijuan, et al.
Publicado: (2020)

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
por: Zekri, Jamal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_opi5crlmf7eb5levphsgrq740b